Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333448 | 0.95 | ROCK2 (0.43) | ROCK2TDP1RAB9AKDM4EDRD1 | |
| SCHEMBL333587 | 0.93 | RAB9A (0.43) | ROCK2TDP1RAB9AKDM4EMEN1 | |
| SCHEMBL5506893 | 0.85 | RAB9A (0.40) | ROCK2RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL333558 | 0.80 | TP53 (0.43) | ROCK2MEN1KMT2APTGES | |
| SCHEMBL1407297 | 0.80 | KDM4E (0.40) | KDM4EMEN1KMT2AHTTPTGES | |
| SCHEMBL333970 | 0.79 | MEN1 (0.39) | KDM4EMEN1KMT2AALDH1A1HTT | |
| SCHEMBL334068 | 0.79 | MEN1 (0.39) | TDP1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL333405 | 0.79 | TP53 (0.42) | ROCK2RAB9AMEN1KMT2APTGES | |
| SCHEMBL333738 | 0.78 | PPARG (0.48) | KDM4EPTGES | |
| SCHEMBL333958 | 0.78 | KDM4E (0.42) | KDM4EMEN1KMT2AHTTPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097623-B2 | 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics | BIOLIPOX AB (SE) | 2012-01-17 | — | — | US | disclosed |
| EP-1841735-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | ROCK2 386/4885TDP1 1742/4885RAB9A 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.